<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>164(2)</volume><submitter>Dimov D</submitter><funding>Universität Bielefeld</funding><pubmed_abstract>&lt;h4>Purpose&lt;/h4>Multifocal/multicentric glioblastomas (mGBM) account for up to 20% of all newly diagnosed glioblastomas. The present study investigates the impact of cytoreductive surgery on survival and functional outcomes in patients with mGBM.&lt;h4>Methods&lt;/h4>We retrospectively reviewed clinical and imaging data of 71 patients with newly diagnosed primary (IDH1 wildtype) mGBM who underwent operative treatment in 2015-2020 at the authors' institution. Multicentric/multifocal growth was defined by the presence of ≥ 2 contrast enhancing lesions ≥ 1 cm apart from each other.&lt;h4>Results&lt;/h4>36 (50.7%) patients had a resection and 35 (49.3%) a biopsy procedure. MGMT status, age, preoperative KPI and NANO scores as well as the postoperative KPI and NANO scores did not differ significantly betwe</pubmed_abstract><journal>Journal of neuro-oncology</journal><pagination>447-459</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10522503</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The role of cytoreductive surgery in multifocal/multicentric glioblastomas.</pubmed_title><pmcid>PMC10522503</pmcid><pubmed_authors>Berger B</pubmed_authors><pubmed_authors>Brainman D</pubmed_authors><pubmed_authors>Grote A</pubmed_authors><pubmed_authors>Coras R</pubmed_authors><pubmed_authors>Simon M</pubmed_authors><pubmed_authors>Dimov D</pubmed_authors></additional><is_claimable>false</is_claimable><name>The role of cytoreductive surgery in multifocal/multicentric glioblastomas.</name><description>&lt;h4>Purpose&lt;/h4>Multifocal/multicentric glioblastomas (mGBM) account for up to 20% of all newly diagnosed glioblastomas. The present study investigates the impact of cytoreductive surgery on survival and functional outcomes in patients with mGBM.&lt;h4>Methods&lt;/h4>We retrospectively reviewed clinical and imaging data of 71 patients with newly diagnosed primary (IDH1 wildtype) mGBM who underwent operative treatment in 2015-2020 at the authors' institution. Multicentric/multifocal growth was defined by the presence of ≥ 2 contrast enhancing lesions ≥ 1 cm apart from each other.&lt;h4>Results&lt;/h4>36 (50.7%) patients had a resection and 35 (49.3%) a biopsy procedure. MGMT status, age, preoperative KPI and NANO scores as well as the postoperative KPI and NANO scores did not differ significantly betwe</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Sep</publication><modification>2025-04-04T21:46:06.885Z</modification><creation>2025-04-04T21:46:06.885Z</creation></dates><accession>S-EPMC10522503</accession><cross_references><pubmed>37697210</pubmed><doi>10.1007/s11060-023-04410-7</doi></cross_references></HashMap>